Paolo Macor
Overview
Explore the profile of Paolo Macor including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
72
Citations
1285
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Durigutto P, Grimaldi M, Bozzer S, Raschi E, Meroni P, Tedesco F, et al.
Front Immunol
. 2025 Mar;
16:1520619.
PMID: 40083554
Anti-phospholipid syndrome (APS) is a systemic autoimmune disease characterized by thrombotic vascular occlusion and maternal morbidity. Anti-coagulants remain pivotal drugs for the management of APS, but a significant proportion of...
2.
Grimaldi M, Bozzer S, Sjostrom D, Andersson L, Mollnes T, Nilsson P, et al.
Front Immunol
. 2025 Feb;
15:1509322.
PMID: 39911576
Introduction: The functionalization of nanoparticles (NPs) with an antiCD19 targeting mechanism represents a promising approach for the selective delivery of drugs and nucleic acids into normal and tumor B cells....
3.
Mossenta M, Argenziano M, Capolla S, Busato D, Durigutto P, Mangogna A, et al.
Nanomedicine (Lond)
. 2025 Jan;
20(3):255-270.
PMID: 39815170
Background: Drug delivery strategies using chitosan nanobubbles (CS-NBs) could be used to reduce drug side effects and improve outcomes in hepatocellular carcinoma (HCC) treatment. To enhance their action, a targeting...
4.
Bozzer S, Grimaldi M, De Maso L, Manfredi M, Toffoli G, Dal Bo M, et al.
Int J Nanomedicine
. 2024 Dec;
19:13267-13286.
PMID: 39679253
Purpose: In the bloodstream, nanoparticles (NPs) interact with serum proteins to form the protein corona, which includes both opsonins, promoting NP recognition and elimination, and dysopsonins, which can inhibit opsonin...
5.
Di Stasi A, Bozzer S, Pacor S, de Pascale L, Morici M, Favero L, et al.
Open Biol
. 2024 Dec;
14(12):240286.
PMID: 39626774
Proline-rich antimicrobial peptides (PrAMPs) have gained attention due to their antimicrobial properties and low cytotoxicity. B7-005, a small optimized PrAMP, exhibits a broader spectrum of activity than native PrAMPs, due...
6.
Di Cintio F, Argenziano M, Scomparin A, Capolla S, Busato D, Steffe A, et al.
Nanomedicine (Lond)
. 2024 Dec;
20(1):23-36.
PMID: 39620421
Background: Recently, we developed AT101, an IgM-class mouse monoclonal antibody directed against glypican-1 (GPC1), a proteoglycan that can be considered as useful target for glioblastoma multiforme (GBM) treatment being specifically...
7.
Ballarin L, Peronato A, Malagoli D, Macor P, Sacchi S, Sales G, et al.
Int J Mol Sci
. 2024 Nov;
25(22).
PMID: 39596065
The complement system is a pivotal component of innate immunity, extensively studied in vertebrates but also present in invertebrates. This study explores the existence of a terminal complement pathway in...
8.
Busato D, Capolla S, Durigutto P, Mossenta M, Bozzer S, Sblattero D, et al.
J Transl Med
. 2023 Nov;
21(1):864.
PMID: 38017492
Background: Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive cancers with a very low survival rate at 5 years. The use of chemotherapeutic agents results in only modest...
9.
Capolla S, Colombo F, De Maso L, Mauro P, Bertoncin P, Kahne T, et al.
J Nanobiotechnology
. 2023 Oct;
21(1):376.
PMID: 37838659
Background: Nanoparticles represent one of the most important innovations in the medical field. Among nanocarriers, polymeric nanoparticles (PNPs) attracted much attention due to their biodegradability, biocompatibility, and capacity to increase...
10.
Riccardi F, Dal Bo M, Macor P, Toffoli G
Front Pharmacol
. 2023 Oct;
14:1274088.
PMID: 37790810
Antibody-Drug Conjugates (ADCs) represent an innovative class of potent anti-cancer compounds that are widely used in the treatment of hematologic malignancies and solid tumors. Unlike conventional chemotherapeutic drug-based therapies, that...